Alan Graff

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril

HR Black, Alan Graff, D Shute et al. · Journal of Human Hypertension · 1997 · 120 citations

Hypertension, Cardiovascular Disease, Antihypertensive Therapy +7

Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy

JR Benz, HR Black, Alan Graff et al. · Journal of Human Hypertension · 1998 · 116 citations

Hypertension, Medicine, Antihypertensive Therapy +7

Comparison of Amlodipine and Benazepril Monotherapy to Amlodipine Plus Benazepril In Patients with Systemic Hypertension: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study

William H. Frishman, C. Venkata S. Ram, F. Gilbert McMahon et al. · The Journal of Clinical Pharmacology · 1995 · 92 citations

A Titrate-to-Goal Study of Switching Patients Uncontrolled on Antihypertensive Monotherapy to Fixed-Dose Combinations of Amlodipine and Olmesartan Medoxomil ± Hydrochlorothiazide

Willa A. Hsueh, Shawna D. Nesbitt, Thomas J. Littlejohn et al. · Journal of Clinical Hypertension · 2011 · 83 citations · Full text

Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: A double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults

James L. Pool, Robert Glazer, Myron H. Weinberger et al. · Clinical Therapeutics · 2007 · 82 citations

Hypertensive Adults, Non-pharmacological Intervention, Hypertension +7